Logo

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

Share this

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

Shots:

  • The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in patients with HER2-positive eBC- being treated with neoadjuvant and adjuvant setting
  • The P-III FeDeriCa study results: reduction in the time spent for receiving treatment- loading dose & maintenance dose (8min. & 5min. vs 150min. & 60min.-150min.); safety profile is consistent with IV regimen respectively
  • The FDC regimen combines Perjeta and Herceptin via Halozyme Therapeutics’ Enhanze drug delivery technology- which is based on rHuPH20 enzyme- work by optimizing SC drug delivery to co-administer therapies

Click here to­ read full press release/ article

Ref: Roche | Image: Roche

 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions